Alumni
This person is a member of Sanger Institute Alumni.
My previous work focused on using human embryonic stem cells as a cell model from which to interrogate the signalling mechanisms governing the derivation of hepatic and neural precursors.
Currently, as part of the Yusa group, I am utilising CRISPR/Cas9 mediated genome-wide screening approaches to identify reprogramming factors involved in the conversion of adult heart fibroblast into cardiac progenitor cells.
This is in collaboration with AstraZeneca, with the ultimate goal of being able to develop new drugs which can facilitate this reprogramming in vivo.